EU Market Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EU Market Challenges


Pharmaceutical Technology Europe
Volume 23, Issue 10


Michael Rooney is product supply manager at Almac.
Although the European market is approximately 50% smaller than the US in terms of landmass, the population of Europe is approximately 50% larger and this presents a huge market opportunity. At our company, we have witnessed a steady increase in the number of US companies taking advantage of European market opportunities, particularly for niche biopharmaceutical and orphan drug products. In return, this has increased the outsourcing requirements for country specific-packaging and temperature-sensitive distribution services. To meet this demand, we have increased investment in client dedicated cold and frozen storage and developed a late-stage customisation suite for country specific packaging.

In addition to this, we have seen further growth across services in pharmaceutical development, commercial manufacture and packaging. Client requirements for bespoke solutions for biopharmaceutical packaging and distribution, as well as traditional toll manufacture of solid oral dosage forms (branded and generic) are also on the increase.

The challenges of the EU marketplace

The key challenges for a company launching drug product in the European marketplace can be summarised in three simple categories:

Regulatory and quality differentiations

Europe has different regulatory and quality requirements compared with the US. For instance, all products manufactured outside of Europe must undergo EU import testing according to Directive 2001/83/EC Article 51 to ensure they are compliant with the specifications outlined in the marketing authorisation application (MAA). Within Europe, all drug products must be released onto the market by the Qualified Person (QP) to confirm that the product is fit for purpose and has been processed to cGMP standards. These two requirements are unique to Europe, which is why client companies need to to ensure they select a CMO with quality resources and regulatory knowledge and experience in this region.

Impact of multiple languages on packaging requirements

One of the biggest challenges to entering the European market is the multitude of languages, which results in a large number of associated country-specific pack formats. Within the 27 member states of the EU, there are 150 regional and minority languages, of which 23 are recognised working languages. Labelling and packaging needs to be in member state language, requiring design, generation and management of all packaging components, including labels, Patient Information Leaflets (PILs) and cartons, for example.

For our clients, regional (multilingual) packs coupled to the application of blue box (country specific detail) at our late-stage labelling operation have proved a success. Applying country specific blue box information to the packaging commits a unit of drug product to that particular market. Partnering with CMOs that provide late-stage customisation enables pharma companies to benefit from flexible stock utilisation, resulting in the ability to be responsive to fluctuations in various market demands, as well as to eliminate excess storage of stock.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here